Policy Forum 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease

[1]  Jens C. Pruessner,et al.  Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation , 2015, Alzheimer's & Dementia.

[2]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[3]  H. Soininen,et al.  A MULTIDOMAIN, TWO-YEAR, RANDOMIZED CONTROLLED TRIAL TO PREVENT COGNITIVE IMPAIRMENT: THE FINGER STUDY , 2014, Alzheimer's & Dementia.

[4]  Maria C. Carrillo,et al.  International Alzheimer's Disease Research Portfolio (IADRP) aims to capture global Alzheimer's disease research funding , 2014, Alzheimer's & Dementia.

[5]  D. Bennett,et al.  Alzheimer's disease in African Americans: risk factors and challenges for the future. , 2014, Health affairs.

[6]  R. Egge.  The Alzheimer's Study Group's recommendations five years later: planning has advanced, but agenda remains unfinished. , 2014, Health affairs.

[7]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[8]  W. Klunk,et al.  Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture , 2013, Neuron.

[9]  Angela Cacace,et al.  Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease , 2013, Alzheimer's & Dementia.

[10]  R. Schilsky,et al.  Reevaluating the Accelerated Approval Process for Oncology Drugs , 2013, Clinical Cancer Research.

[11]  R. Katz,et al.  Regulatory innovation and drug development for early-stage Alzheimer's disease. , 2013, The New England journal of medicine.

[12]  K. Blennow,et al.  Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.

[13]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[14]  Paul Edison,et al.  Drug repositioning for Alzheimer's disease , 2012, Nature Reviews Drug Discovery.

[15]  R. Petersen,et al.  The epidemiology of Alzheimer’s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials , 2012, Alzheimer's & Dementia.

[16]  L. Fratiglioni,et al.  Dementia prevention: current epidemiological evidence and future perspective , 2012, Alzheimer's Research & Therapy.

[17]  J. Karlawish,et al.  Countrywide strategic plans on Alzheimer’s disease: Developing the framework for the international battle against Alzheimer’s disease , 2011, Alzheimer's & Dementia.

[18]  Irving E. Vega,et al.  Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[20]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[21]  J. Karlawish,et al.  Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials , 2010, Alzheimer's Research & Therapy.

[22]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[23]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[24]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[25]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[26]  K. Langa,et al.  Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites , 2009, Alzheimer's & Dementia.

[27]  T. Meuser,et al.  Predictors of Physician Referral for Patient Recruitment to Alzheimer Disease Clinical Trials , 2009, Alzheimer disease and associated disorders.

[28]  K. Langa,et al.  Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study , 2007, Neuroepidemiology.

[29]  J. Trojanowski,et al.  Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery , 2006, Alzheimer's & Dementia.

[30]  J. Demirovic,et al.  Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. , 2003, Annals of epidemiology.

[31]  D. Bennett,et al.  Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. , 2003, Archives of neurology.

[32]  R. Costa,et al.  Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan , 2001, Neurology.

[33]  Habib Zaidi,et al.  Amyloid-β positron emission tomography imaging probes: a critical review. , 2013, Journal of Alzheimer's disease : JAD.

[34]  Keith A. Johnson,et al.  ORAL SESSIONS: IC-O3 EMERGING TECHNIQUES IC-O3-01 THE CENTILOID SCALE: STANDARDIZATION OF AMYLOID IMAGING MEASURES , 2013 .